Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …

Interleukins and associated cytokines serve as the means of communication for innate and
adaptive immune cells as well as non-immune cells and tissues. Thus, interleukins have a …

Vα24-invariant natural killer T cells (NKTs) have anti-tumor properties that can be enhanced
by chimeric antigen receptors (CARs). Here we report updated interim results from the first-in …

Natural Killer (NK) cells and CD8+ cytotoxic T cells are two types of immune cells that can
kill target cells through similar cytotoxic mechanisms. With the remarkable success of …

T cells engineered to express chimeric antigen receptors (CARs) with tumor specificity have
shown remarkable success in treating patients with hematologic malignancies and …

Cell therapies present an entirely new paradigm in drug development. Within this class,
immune cell therapies are among the most advanced, having already demonstrated …

Cancer immunotherapy with autologous chimeric antigen receptor (CAR) T cells faces
challenges in manufacturing and patient selection that could be avoided by using 'off-the …

Chimeric antigen receptor T (CAR-T) cell therapy achieved extraordinary achievements
results in antitumor treatments, especially against hematological malignancies, where it …

Background Glypican-3 (GPC-3) is an oncofetal protein that is highly expressed in various
solid tumors, but rarely expressed in healthy adult tissues and represents a rational target of …

Gangliosides are carbohydrate-containing sphingolipids that are widely expressed in
normal tissues, making most subtypes unsuitable as targets for cancer therapy. However …